Formulation and Evaluation of an Effervescent, Gastroretentive Drug-Delivery System - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Formulation and Evaluation of an Effervescent, Gastroretentive Drug-Delivery System
The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.

Pharmaceutical Technology
Volume 10, Issue 34, pp. 60-71


1. L.F. Prescott and W.S. Nimmo, Novel Drug Delivery and Its Therapeutic Application, F.L. Prescott, Ed. (John Wiley and Sons, Oxford, UK, 1989), pp. 1–11.

2. Y.W. Chien, "Controlled and Modulated-Release Drug Delivery Systems," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan, Eds. (Marcel Dekker, New York, 1990), p. 280.

3. G. Chawla et al., Pharm. Technol. 27 (7), 50–68 (2003).

4. Medicines Complete, "Ibuprofen/Indomethacin,", accessed Dec. 19, 2006.

5. J.C. Valle-Jones, J. Smith, and D. Rowely-Jones, Br. J. Clin. Pract. 38 (7), 353–358 (1984).

6. T.H. Kantor, Ann. Intern. Med. 91 (6), 877–882 (1979).

7. A. Avgerinos and S. Malamataris, Int. J. Pharm. 63 (1), 77–80 (1990).

8. N. Sarkar et al., Curr. Ther. Res. Clin. Exp. 44 (6), 11–21 (1988).

9. M. Galeon et al., Curr. Ther. Res. Clin. Exp. 29 (4), 217–234 (1981).

10. S. Bolton and Charles Bon, "Factorial Designs," in Pharmaceutical Statistics: Practical and Clinical Applications, J. Swarbrick, Ed. (Marcel Dekker, New York, 3rd ed., 1984), pp. 265–285.

11. N.A. Armstrong and K.C. James, "Factorial Designs of Experiments," in Understanding Experimental Design and Interpretation in Pharmaceutics, (Ellis Harwood, London, 1990), pp. 27–54.

12. R. Ziyaur, A. Mushir, and R.K. Khar, Acta Pharm. 56 (2), 49–57 (2006).

13. N. Tomoya et al., Chem. Pharm. Bull. 54 (6), 14–51 (2006).

14. B.S. Dave, A.F. Amin, and M.M. Patel, AAPS PharmSciTech 5 (2), 45–49 (2004).

15. USP 27–NF 22 (USP, Rockville, MD, 2003), pp. 953–955.

16. M. Rosa, H. Zia, and T. Rhodes, Int. J. Pharm. 105 (34), 65–70 (1994).

17. G.S. Banker and N.R. Anderson, "Tablets," in The Theory and Practice of Industrial Pharmacy, L. Lachmann, H.A. Liberman, and J.L. Kaing, Eds. (Varghese Publishing House, Mumbai, 3rd ed., 1987), pp. 295–299.

18. "Tablets" (Indian Pharmacopoeia, (Controller of Publication, Delhi, India, Vol. II, 1996), pp. 734–736.

19. J. Castellanos, M.R.H. Zia, and C.T. Rhodes, Int. J. Pharm. 105 (34), (Apr25), 65–70 (1994).

20. J.E. Devereux, J.M. Newton, and M.B. Short, J. Pharm. Pharmacol. 42 (8), 500–501 (1990).

21. V.S. Chitnis, V.S. Malshe, and J.K. Lalla, Drug Dev. Ind. Pharm. 17 (10), 879–892 (1991).

22. G.M. Khan, Sciences 1 (8), 350–354 (2001).

23. D.M. Morkhade, Indian J. Pharm. Sci. 68 (3), 53–58 (2006).

24. T. Higuchi, J. Pharm. Sci. 52 (12), 1145–1149 (1963).

25. N.A. Peppas and J.J. Sahlin, Int. J. Pharm. 57 (1), 169–172 (1989).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here